Would I buy and hold CSL and Cochlear shares for 10 years?

These two businesses have different growth stories, but both stand out to me long term.

Some ASX shares are worth considering for much longer than the next few months.

For me, healthcare is one area where taking a long-term approach could be particularly rewarding.

Growing demand for medical treatments, ageing populations, and ongoing innovation can provide opportunities for established companies to keep expanding.

And there are two Australian healthcare businesses I would be comfortable buying and holding for the next decade.

Doctor with stethoscope typing on her computer.

Image source: Getty Images

CSL Ltd (ASX: CSL)

CSL has endured a difficult period, with disappointing earnings growth, operational challenges, and a substantial loss of investor confidence.

But I think the next 10 years could tell a much more positive story. The biotechnology company remains one of the world's leading providers of plasma-derived medicines, including immunoglobulin therapies used to treat patients with immune deficiencies and other serious conditions.

Demand for these treatments continues to grow, providing CSL with an opportunity to increase sales over time.

I also think there's considerable potential to improve profitability. CSL has been working to make plasma collection more efficient, improve manufacturing productivity, and simplify its operations.

These improvements could have a meaningful impact on earnings as the business grows.

And there's now a new leadership chapter approaching. Last week, CSL announced that Deborah Waterhouse would become CEO in February 2027. She brings extensive international pharmaceutical experience, which I think could be valuable as CSL works to restore growth.

There are still challenges to overcome, particularly competition affecting some of its treatments and pressure on its vaccines business.

But I believe CSL's market position, growing demand for plasma therapies, and opportunities for greater efficiency could support a substantial recovery over the coming decade.

Cochlear Ltd (ASX: COH)

Cochlear is another healthcare share I would be happy to own for 10 years. The company is a global leader in hearing implants, helping people with severe hearing loss regain access to sound.

What I like is the enormous opportunity to reach more patients. Cochlear estimates that fewer than 5% of eligible adults in developed markets currently receive cochlear implants.

That gives it a substantial opportunity to grow by improving awareness and making it easier for patients to access treatment. And today's annual general meeting update provided some encouraging developments.

Management reaffirmed its FY27 underlying net profit guidance of $330 million to $350 million, compared with $322 million in FY26.

The company also reported strong adoption of its newer Nucleus Nexa implant, which accounted for more than 95% of implant sales in developed markets by June.

I think continued product innovation could be an important growth driver. Cochlear is also progressing clinical studies of a fully implantable hearing system, which could eventually offer patients a treatment without an external sound processor.

Meanwhile, the company is expanding referral initiatives to help more eligible adults receive treatment.

Looking a decade ahead, I think Cochlear has an excellent opportunity to expand its patient base while maintaining its technological leadership.

Foolish takeaway

I would be comfortable buying both companies today and holding them for the next 10 years.

CSL shares offer an opportunity to benefit from a recovery in profitability alongside growing demand for its medicines.

Cochlear has a substantial market opportunity that I think could support growth well beyond its current earnings recovery.

For me, both remain high-quality Australian healthcare shares with plenty of reasons to be optimistic about their long-term futures.

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »